Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07009262 · ClinicalTrials.gov registry record
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
A clinical trial, sponsored by KalVista Pharmaceuticals.
- Completed
- Registry status
- 88
- Enrollment target
NCT07009262: Completed study, sponsored by KalVista Pharmaceuticals.
NCT07009262 is a clinical trial that has completed, run by KalVista Pharmaceuticals. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07009262 has completed, sponsored by KalVista Pharmaceuticals.
- COMPLETED
- Registry status
- 88 participants
- Enrollment target
Study Summary
Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.
Primary Outcome
time to beginning of symptom relief defined as at least ''a little better'' (2 time points in a row)
Interventions
- OTHER Inapplicable
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2025-11-25 |
What the finished NCT07009262 record still lists
NCT07009262 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 88 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Inapplicable is the first listed.
NCT07009262 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07009262 about?
NCT07009262 is a clinical study titled "A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks". Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and sever...
What is the current status of trial NCT07009262?
This trial is currently completed. The enrollment target is 88 participants. The study started on 2025-04-21. Estimated completion is 2025-11-25.
What interventions are being tested in trial NCT07009262?
The interventions under investigation include: Inapplicable (OTHER).
Who is sponsoring clinical trial NCT07009262?
This trial is sponsored by KalVista Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI